Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
Rhea-AI Summary
Reviva (OTCQB: RVPH) announced that Founder, President and CEO Laxminarayan Bhat, PhD, will join a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase on Wednesday, May 20, 2026, from 2:40–3:00 PM ET. Investors can register to watch the session online.
Positive
- None.
Negative
- None.
News Market Reaction – RVPH
In the May 18 session, RVPH gained 23.31%, reflecting a significant positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | Earnings and pipeline | Positive | +10.8% | Narrower loss, higher cash, patent steps and RECOVER-2 planning for brilaroxazine. |
| Apr 23 | Investor fireside chat | Neutral | -4.2% | Announcement of A.G.P.-hosted discussion on brilaroxazine milestones and outlook. |
| Apr 15 | Shareholder letter | Positive | +3.4% | Update on financing, cash runway into 2027, and RECOVER-2 clinical timelines. |
| Mar 30 | Full-year earnings | Negative | -11.0% | Reported 2025 net loss and need for second Phase 3 trial per FDA feedback. |
| Mar 23 | Public equity offering | Negative | +11.6% | Dilutive $10M equity and warrant offering to fund RECOVER-2 and operations. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news and earnings have mostly seen price moves aligned with the tone of the announcements, with one notable divergence on a dilutive offering that was met by a positive reaction.
Over the past few months, RVPH has reported multiple financing and clinical-planning updates focused on brilaroxazine. Earnings releases on Mar 30, 2026 and May 13, 2026 highlighted narrowing losses, cash levels, and the planned RECOVER-2 Phase 3 trial, with mixed but generally aligned price reactions. Capital raises, including a $10.0 million public offering on Mar 20, 2026, funded operations into Q1 2027. Non-fundamental communications such as fireside chats and shareholder letters have produced modest, directionally consistent moves, framing today’s conference participation as part of ongoing investor outreach.
Key Terms
central nervous system (cns) medical
cardiometabolic medical
otcqb financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.
Fireside Chat Details:
Time: 2:40-3:00 PM ET
Date: Wednesday, May 20, 2026
Investors can register for the conference and view the fireside chat here.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
PJ Kelleher
pkelleher@lifesciadvisors.com
